Clinical Trial Update: Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating Imatinib Mesylate for unresectable or metastatic gastrointestinal stromal tumor; the trial status is currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Gastrointestinal Stromal Tumor | Phase 3 | Status: UNKNOWN